{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:16:08Z","timestamp":1793852168669,"version":"4.6.1"},"reference-count":29,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,15]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Discontinuation of lenalidomide maintenance after autologous stem cell transplantation is a burning question within the multiple myeloma (MM) community, especially after the inclusion of minimal residual disease (MRD) in the disease response criteria. In this prospective study, we evaluated the conversion to MRD positivity, the treatment-free survival (TFS), and the progression-free survival (PFS) in 52 patients with MM who discontinued lenalidomide maintenance after achieving sustained bone marrow and imaging MRD negativity for 3 years. Patients who developed MRD positivity after lenalidomide discontinuation restarted lenalidomide maintenance at the same dose. The median follow-up from lenalidomide discontinuation was 3 years. Overall, 12 (23%) patients obtained MRD positivity and restarted lenalidomide maintenance. Only 4 (7.6%) patients progressed; 3 had a biochemical progression and 1 had a clinical progression. The overall median PFS was not reached, whereas the 7-year PFS from diagnosis was 90.2%. The 1-, 2-, and 3-year TFS rates were 93.9%, 91.6%, and 75.8%, respectively, whereas the 1-, 2-, and 3-year landmark PFS rates from maintenance discontinuation (study entrance) were 96.0%, 96.0%, and 92.9%, respectively. There were no statistically significant associations among age, sex, Second Revision International Staging System, type of induction therapy, and use of consolidation therapy and the effect outcomes of PFS and TFS. We conclude that maintenance discontinuation after 3 years of sustained marrow and imaging MRD negativity is associated with low rates of MRD conversion and progressive disease. Thus, in the era of modern antimyeloma treatments, a subgroup of patients may remain treatment free while in complete remission without jeopardizing disease response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024027686","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T12:19:16Z","timestamp":1740572356000},"page":"2353-2360","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4673-171X","authenticated-orcid":false,"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1152-6959","authenticated-orcid":false,"given":"Ioannis V.","family":"Kostopoulos","sequence":"additional","affiliation":[{"name":"2Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3407-5994","authenticated-orcid":false,"given":"Evangelos","family":"Eleutherakis-Papaiakovou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kanellias","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Spiliopoulou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-2447","authenticated-orcid":false,"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-8900","authenticated-orcid":false,"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6926-0351","authenticated-orcid":false,"given":"Foteini","family":"Theodorakakou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1229","authenticated-orcid":false,"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6954-0740","authenticated-orcid":false,"given":"Ourania E.","family":"Tsitsilonis","sequence":"additional","affiliation":[{"name":"2Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"},{"name":"3Department of Medicine, Korea University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"29","key":"2025051511212148000_bib1","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2025051511212148000_bib2","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/1078-0432.CCR-21-1059","article-title":"Minimal residual disease in myeloma: application for clinical care and new drug registration","volume":"27","author":"Anderson","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2025051511212148000_bib3","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A\u00a0large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2025051511212148000_bib4","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1097\/HS9.0000000000000300","article-title":"Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy","volume":"3","author":"Terpos","year":"2019","journal-title":"Hemasphere"},{"issue":"7","key":"2025051511212148000_bib5","first-page":"2049","article-title":"Role of minimal residual disease assessment in multiple myeloma","volume":"109","author":"Szalat","year":"2024","journal-title":"Haematologica"},{"key":"2025051511212148000_bib6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3389\/fonc.2020.00860","article-title":"Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches","volume":"10","author":"Kostopoulos","year":"2020","journal-title":"Front Oncol"},{"issue":"10","key":"2025051511212148000_bib7","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/ajh.27029","article-title":"Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: the MD Anderson experience","volume":"98","author":"Pasvolsky","year":"2023","journal-title":"Am J Hematol"},{"key":"2025051511212148000_bib8","doi-asserted-by":"crossref","first-page":"102099","DOI":"10.1016\/j.eclinm.2023.102099","article-title":"Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial","volume":"62","author":"Jones","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"4","key":"2025051511212148000_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2025051511212148000_bib10","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma","volume":"142","author":"Rosinol","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2025051511212148000_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2025051511212148000_bib12","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood.2023022080","article-title":"Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma","volume":"143","author":"D'Agostino","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2025051511212148000_bib13","first-page":"910","article-title":"The perspective of Romanian patients on continuous therapy for multiple myeloma","volume":"14","author":"Irimia","year":"2024","journal-title":"J\u00a0Pers Med"},{"issue":"7","key":"2025051511212148000_bib14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/s41375-020-0724-1","article-title":"Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial","volume":"34","author":"Goldschmidt","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"2025051511212148000_bib15","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"2025051511212148000_bib16","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"2025051511212148000_bib17","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"23","key":"2025051511212148000_bib18","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2025051511212148000_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.2022016782","article-title":"MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials","volume":"141","author":"Paiva","year":"2023","journal-title":"Blood"},{"issue":"suppl 16","key":"2025051511212148000_bib20","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/JCO.2024.42.16_suppl.7502","article-title":"Daratumumab (DARA)\u00a0+ bortezomib\/lenalidomide\/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) in the PERSEUS trial","volume":"42","author":"Rodr\u00edguez-Otero","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2025051511212148000_bib21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.hoc.2023.12.009","article-title":"Measurable residual disease and decision-making in multiple myeloma","volume":"38","author":"Derman","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"2025051511212148000_bib22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-024-01156-x","article-title":"Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025051511212148000_bib23","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2025051511212148000_bib24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2023022083","article-title":"Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma","volume":"143","author":"Guerrero","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025051511212148000_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"25","key":"2025051511212148000_bib26","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.21.02228","article-title":"Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk","volume":"40","author":"de Tute","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2025051511212148000_bib27","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.2022018339","article-title":"Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial","volume":"141","author":"Panopoulou","year":"2023","journal-title":"Blood"},{"issue":"suppl 15","key":"2025051511212148000_bib28","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","article-title":"Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM)","volume":"38","author":"Hari","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2025051511212148000_bib29","first-page":"2420","article-title":"Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible","volume":"109","author":"Engelhardt","year":"2024","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/20\/2353\/2374666\/blood_bld-2024-027686-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/20\/2353\/2374666\/blood_bld-2024-027686-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:21:33Z","timestamp":1747308093000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/20\/2353\/535778\/Sustained-bone-marrow-and-imaging-MRD-negativity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":29,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,5,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024027686","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}